Frontlight ResearchEarly access
Active, not recruitingPhase 3
A Study of Efficacy and Safety of TLL-018 in CSU Participants
Key facts
- Who runs it
- Hangzhou Highlightll Pharmaceutical Co., Ltd
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 3
- People taking part
- 440 people enrolled
- Started
- 27 Mar 2024
- Expected to end
- 30 Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- TLL-018 tablets
- Placebo tablets
- Record updated
- 3 June 2026
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (18)Hide the full registry criteria
Who can take part
- Aged between 18 and 75
- Diagnosis of CSU refractory to secomd-generation H1-AH
- CSU diagnosis for ≥ 6 months
- The presence of itch and hivese despite current use of an approved dose of H1-AH prior to screening visit
- UAS7 score (range 0-42) ≥ 16 and itch component of UAS7 (range 0-21) ≥ 8 during 7 days prior to randomization (Day 1)
- Participants were required to take a stable standard dose of a second generation H1-AH concomitantly according to local guidelines
- Willing and able to complete UPDD for the duration of the study
- Evidence of urticaria confirmed by the investigator prior to randomization
- Women of Child Bearing Potential (WOCBP) should not be pregnant or breastfeeding and the pregnancy test should be negative before randomization
- Participants (whether male or female) should have adequate barrier contraception during the whole treatment period and at least 90 days after treatment; subjects should avoid the sperm or ovum donation for at least six months after treatment
Who cannot take part
- Participants with any of the following prior therapies or concomitant medications cannot be enrolled:; Have received any study drug within 4 weeks or less than 5 elimination of half-life period before randomization (whichever is longer); Have received biological agent within 3 months or 5 elimination of half-life period prior to randomization (whichever is longer); Have received immunosuppressive/modulatory drug within 4 weeks before randomization; Have received any live vaccine within 2 months before randomization or plan to receive a live vaccine during the study
- Have experienced major surgery within 4 weeks before randomization, or expected to receive major surgical treatment after enrollment
- Have donated blood more than 400 ml or received blood transfusion within 3 months prior to the study
- History of drug or alcohol abuse within 6 months prior to screening
- Participants meeting Chinese Guidelines for Urticaria Diagnosis and Treatment with the following concomitant diseases cannot be enrolled:; Clearly defined underlying etiology for chronic urticarias other than CSU. E.g. induced urticaria, including but not limited to artificial urticaria; Any disease, which may have symptoms of urticaria and/or angioedema, including but not limited to urticaria and vasculitis; Suffering from other chronic pruritic diseases that may affect the judgment of efficacy results, such as psoriasis, atopic dermatitis, etc; Previous malignancy, herpes zoster, active tuberculosis; Other symptoms of progressive or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiovascular, neurological, psychiatric, or cerebral disease; Taking part in this study, in the opinion of the investigator, places the patient at unacceptable risk
- Allergy to ingredients or excipients of H1-AH or TLL-018
- Participants are not appropriate for participation in any other situation or condition in this study
- Laboratory test results are abnormal and may interfere the study judged by investigators
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TLL-018 in Participants With Moderate-to-Severe Chronic Spontaneous Urticaria (CSU) With Inadequate Controll to Second Generation H1-antihistamines.
The 2 groups in the trial
- Arm 1Treatment being tested
TLL018 tablets,1 tablet ,BID
Treatment: TLL-018 tablets
- Arm 2Placebo, for comparison
Placebo tablets, 1 tablet ,BID
Treatment: Placebo tablets
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TLL-018 in Participants With Moderate-to-Severe Chronic Spontaneous Urticaria With Inadequate Controll to Second Generation H1-antihistamines
- Record updated
- 3 June 2026